Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol

BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity....

Descripción completa

Detalles Bibliográficos
Autores principales: Haynes, Richard, Baigent, Colin, Harden, Paul, Landray, Martin, Akyol, Murat, Asderakis, Argiris, Baxter, Alex, Bhandari, Sunil, Chowdhury, Paramit, Clancy, Marc, Emberson, Jonathan, Gibbs, Paul, Hammad, Abdul, Herrington, Will, Jayne, Kathy, Jones, Gareth, Krishnan, Nithya, Lay, Michael, Lewis, David, Macdougall, Iain, Nathan, Chidambaram, Neuberger, James, Newstead, Chas, Pararajasingam, Ravi, Puliatti, Carmelo, Rigg, Keith, Rowe, Peter, Sharif, Adnan, Sheerin, Neil, Sinha, Sanjay, Watson, Chris, Friend, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674985/
https://www.ncbi.nlm.nih.gov/pubmed/23641902
http://dx.doi.org/10.1186/2047-1440-2-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674985/
https://www.ncbi.nlm.nih.gov/pubmed/23641902
http://dx.doi.org/10.1186/2047-1440-2-7

Ejemplares similares